Medicalcv (MM) (NASDAQ:MDCV)
Historical Stock Chart
From Jun 2019 to Jun 2024
MedicalCV Announces Addition of Industry Experts to ATRILAZE(TM)
Research & Development Team
Company Takes Proactive Steps to Enhance Strategic Growth
MINNEAPOLIS, May 26 /PRNewswire-FirstCall/ -- MedicalCV, Inc. (OTC:MDCV)
(BULLETIN BOARD: MDCV) , http://www.medcvinc.com/ , a cardiovascular surgery
device manufacturer, announced today the addition of Gregory G. Brucker, Ph.D.,
and Kenneth W. Grace, Ph.D. to the research & development team.
"Dr. Brucker is a highly-respected expert in the field of laser physics. As our
Principal Scientist, he brings over 15 years of experience working with laser
energy and 20 years of experience in the development of medical devices," said
Adam L. Berman, Vice President of Research & Development. "His expertise in
arrhythmia ablation technologies will be invaluable in our ongoing product
development and market validation initiatives."
"Dr. Grace has over 16 years of experience in the design of complex robotic
systems and micromanipulators applied to cardiac and ophthalmic surgery. As our
Principal Design Engineer, Dr. Grace will be instrumental in the development
and evolution of laser delivery mechanisms for the stand- alone, minimally
invasive (closed-chest, beating heart) surgical procedure of the future,"
continued Berman.
"The addition of these two highly qualified individuals to the research &
development team is a testament to the strong scientific foundation being
established at MedicalCV. We are excited by the addition of such strong talent
as the market validates that coherent laser is the "ideal" energy source for
cardiac tissue ablation as a potential means to treat atrial fibrillation,"
said Marc P. Flores, President and CEO.
About MedicalCV, Inc.
MedicalCV, Inc., a cardiovascular surgery device manufacturer, which focuses on
the development and introduction of products designed to improve patient
outcomes through the early treatment of cardiovascular disorders and disease
specifically, products used by cardiac surgeons to ablate cardiac tissue as a
potential means to treat atrial fibrillation. The Company's core technology is
the ATRILAZE(TM) Surgical Ablation System for use in cardiac tissue ablation
procedures in open-heart surgery. The Company acquired this technology in
August 2003 and received its FDA 510(k) clearance in November 2004. The
ATRILAZE(TM) system is now available commercially for concomitant open-heart
surgical procedures. The Company's common stock is traded on the OTC Bulletin
Board under the symbol "MDCV."
For further information on MedicalCV, Inc., please visit
http://www.medcvinc.com/ . You may register to receive MedicalCV's future press
releases and to be added to the Company's distribution list by visiting:
http://www.roiny.com/form.php .
This release contains certain forward-looking statements of expected future
developments, as defined in the Private Securities Litigation Reform Act of
1995. The forward-looking statements in this release refer to our expectations
regarding disposition of our heart valve business, operating improvements,
development of atrial fibrillation product and minimally invasive treatment of
atrial fibrillation. These forward-looking statements reflect management's
expectations and are based on currently available data; however, actual results
are subject to future risks and uncertainties, which could materially affect
actual performance. Risks and uncertainties that could affect such performance
include, but are not limited to, the following: the Company's ability to fund
significant capital needs; market acceptance in the U.S. of the Company's
cardiovascular products; acceptance of minimally invasive techniques for the
reduction of atrial fibrillation through ablation; potential reductions in
pricing by competitors; the costs of licensing and acquiring new products and
technologies; the time and costs involved in obtaining regulatory clearance for
cardiovascular products; competing technological and market developments;
physician acceptance of the Company's cardiovascular products; dependence upon
governmental reimbursements and third party supplies; and the strength of the
market for cardiovascular products. For more detailed information about these
risks and uncertainties, please review the Company's Annual Report on Form 10-
KSB for the fiscal year ended April 30, 2004 and our 8-K report filed with the
Securities and Exchange Commission on May 17, 2005
These events and uncertainties are difficult or impossible to predict
accurately and many are beyond the Company's control. The Company assumes no
obligation to publicly release the results of any revisions that may be made to
any forward-looking statements to reflect events or uncertainties after the
date of such statements or to reflect the occurrence of anticipated or
unanticipated events.
DATASOURCE: MedicalCV, Inc.
CONTACT: Adam L. Berman, Vice President, Research & Development of
MedicalCV, Inc., +1-651-452-3000, , or Investors: Robert
Giordano, President, +1-212-495-0200, ext. 10, , or Sarah
Shepard, Vice President, +1-212-495-0200, ext. 17, , both
of ROI Group Associates, Inc.
Web site: http://www.roiny.com/form.php
http://www.medcvinc.com/